View Item 

Show simple item record

Cancer biomarkers

dc.contributor.authorHenry, N. Lynn
dc.contributor.authorHayes, Daniel F.
dc.date.accessioned2017-01-10T20:52:13Z
dc.date.available2017-01-10T20:52:13Z
dc.date.issued2012-04
dc.identifier.citation(2012). "Cancer biomarkers." Molecular Oncology 6(2): 140-146.
dc.identifier.issn1574-7891
dc.identifier.issn1878-0261
dc.identifier.urihttps://hdl.handle.net/2027.42/135702
dc.publisherWiley Periodicals, Inc.
dc.subject.otherTumor marker
dc.subject.otherBiomarker
dc.subject.otherCancer
dc.titleCancer biomarkers
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelHematology and Oncology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.contributor.affiliationumUniversity of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, Med Inn Building, Room C450, Ann Arbor, MI 48109-5843, USA
dc.contributor.affiliationother1500 East Medical Center Drive, Comprehensive Cancer Center, Room 6312, Ann Arbor, MI 48109-0942, USA
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/135702/1/mol2201262140.pdf
dc.identifier.doi10.1016/j.molonc.2012.01.010
dc.identifier.sourceMolecular Oncology
dc.identifier.citedreferenceRansohoff, D.F., Gourlay, M.L., 2010. Sources of bias in specimens for research about molecular markers for cancer. J. Clin. Oncol.. 28, 698 – 704.
dc.identifier.citedreferenceMoore, H.M., Kelly, A.B., Jewell, S.D., McShane, L.M., Clark, D.P., Greenspan, R., Hayes, D.F., Hainaut, P., Kim, P., Mansfield, E., Potapova, O., Riegman, P., Rubinstein, Y., Seijo, E., Somiari, S., Watson, P., Weier, H.U., Zhu, C., Vaught, J., 2011. Biospecimen reporting for improved study quality (BRISQ). J. Proteome Res.. 10, 3429 – 3438.
dc.identifier.citedreferenceNational Cancer Institute, http://www.cancer.gov/dictionary?CdrID=45618, (accessed on 27.9.11.).
dc.identifier.citedreferencePaik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F.L., Walker, M.G., Watson, D., Park, T., Hiller, W., Fisher, E.R., Wickerham, D.L., Bryant, J., Wolmark, N., 2004. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med.. 351, 2817 – 2826.
dc.identifier.citedreferencePetricoin, E.F., Ardekani, A.M., Hitt, B.A., Levine, P.J., Fusaro, V.A., Steinberg, S.M., Mills, G.B., Simone, C., Fishman, D.A., Kohn, E.C., Liotta, L.A., 2002. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 359, 572 – 577.
dc.identifier.citedreferencePiccart-Gebhart, M.J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., Cameron, D., Dowsett, M., Barrios, C.H., Steger, G., Huang, C.S., Andersson, M., Inbar, M., Lichinitser, M., Lang, I., Nitz, U., Iwata, H., Thomssen, C., Lohrisch, C., Suter, T.M., Ruschoff, J., Suto, T., Greatorex, V., Ward, C., Straehle, C., McFadden, E., Dolci, M.S., Gelber, R.D., 2005. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med.. 353, 1659 – 1672.
dc.identifier.citedreferenceRansohoff, D.F., 2007. How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. J. Clin. Epidemiol.. 60, 1205 – 1219.
dc.identifier.citedreferenceRebbeck, T.R., Lynch, H.T., Neuhausen, S.L., Narod, S.A., Van’t Veer, L., Garber, J.E., Evans, G., Isaacs, C., Daly, M.B., Matloff, E., Olopade, O.I., Weber, B.L., 2002. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med.. 346, 1616 – 1622.
dc.identifier.citedreferenceRomond, E.H., Perez, E.A., Bryant, J., Suman, V.J., Geyer, C.E., Davidson, N.E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P.A., Swain, S.M., Pisansky, T.M., Fehrenbacher, L., Kutteh, L.A., Vogel, V.G., Visscher, D.W., Yothers, G., Jenkins, R.B., Brown, A.M., Dakhil, S.R., Mamounas, E.P., Lingle, W.L., Klein, P.M., Ingle, J.N., Wolmark, N., 2005. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med.. 353, 1673 – 1684.
dc.identifier.citedreferenceRustin, G.J., van der Burg, M.E., Griffin, C.L., Guthrie, D., Lamont, A., Jayson, G.C., Kristensen, G., Mediola, C., Coens, C., Qian, W., Parmar, M.K., Swart, A.M., 2010. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 376, 1155 – 1163.
dc.identifier.citedreferenceSargent, D.J., Conley, B.A., Allegra, C., Collette, L., 2005. Clinical trial designs for predictive marker validation in cancer treatment trials. J. Clin. Oncol.. 23, 2020 – 2027.
dc.identifier.citedreferenceSimon, R.M., Paik, S., Hayes, D.F., 2009. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J. Natl. Cancer Inst.. 101, 1446 – 1452.
dc.identifier.citedreferenceTaylor, C.F., Paton, N.W., Lilley, K.S., Binz, P.A., Julian, R.K., Jones, A.R., Zhu, W., Apweiler, R., Aebersold, R., Deutsch, E.W., Dunn, M.J., Heck, A.J., Leitner, A., Macht, M., Mann, M., Martens, L., Neubert, T.A., Patterson, S.D., Ping, P., Seymour, S.L., Souda, P., Tsugita, A., Vandekerckhove, J., Vondriska, T.M., Whitelegge, J.P., Wilkins, M.R., Xenarios, I., Yates, J.R., Hermjakob, H., 2007. The minimum information about a proteomics experiment (MIAPE). Nat. Biotechnol.. 25, 887 – 893.
dc.identifier.citedreferenceTeutsch, S.M., Bradley, L.A., Palomaki, G.E., Haddow, J.E., Piper, M., Calonge, N., Dotson, W.D., Douglas, M.P., Berg, A.O., 2009. The evaluation of Genomic applications in practice and prevention (EGAPP) Initiative: methods of the EGAPP Working group. Genet. Med.. 11, 3 – 14.
dc.identifier.citedreferencevan’t Veer, L.J., Paik, S., Hayes, D.F., 2005. Gene expression profiling of breast cancer: a new tumor marker. J. Clin. Oncol.. 23, 1631 – 1635.
dc.identifier.citedreferenceVillanueva, J., Shaffer, D.R., Philip, J., Chaparro, C.A., Erdjument-Bromage, H., Olshen, A.B., Fleisher, M., Lilja, H., Brogi, E., Boyd, J., Sanchez-Carbayo, M., Holland, E.C., Cordon-Cardo, C., Scher, H.I., Tempst, P., 2006. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Invest.. 116, 271 – 284.
dc.identifier.citedreferenceWolff, A.C., Hammond, M.E., Schwartz, J.N., Hagerty, K.L., Allred, D.C., Cote, R.J., Dowsett, M., Fitzgibbons, P.L., Hanna, W.M., Langer, A., McShane, L.M., Paik, S., Pegram, M.D., Perez, E.A., Press, M.F., Rhodes, A., Sturgeon, C., Taube, S.E., Tubbs, R., Vance, G.H., van de Vijver, M., Wheeler, T.M., Hayes, D.F., 2007. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol.. 25, 118 – 145.
dc.identifier.citedreferenceAllegra, C.J., Jessup, J.M., Somerfield, M.R., Hamilton, S.R., Hammond, E.H., Hayes, D.F., McAllister, P.K., Morton, R.F., Schilsky, R.L., 2009. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol.. 27, 2091 – 2096.
dc.identifier.citedreferenceAllred, D.C., 2008. Commentary: hormone receptor testing in breast cancer: a distress signal from Canada. Oncologist. 13, 1134 – 1136.
dc.identifier.citedreferenceBaggerly, K.A., Morris, J.S., Coombes, K.R., 2004. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics. 20, 777 – 785.
dc.identifier.citedreferenceBang, Y.J., Van Cutsem, E., Feyereislova, A., Chung, H.C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., Aprile, G., Kulikov, E., Hill, J., Lehle, M., Ruschoff, J., Kang, Y.K., 2010. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 376, 687 – 697.
dc.identifier.citedreferenceBossuyt, P.M., Reitsma, J.B., Bruns, D.E., Gatsonis, C.A., Glasziou, P.P., Irwig, L.M., Moher, D., Rennie, D., de Vet, H.C., Lijmer, J.G., 2003. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann. Intern. Med.. 138, W1 – 12.
dc.identifier.citedreferenceBurstein, H.J., Mangu, P.B., Somerfield, M.R., Schrag, D., Samson, D., Holt, L., Zelman, D., Ajani, J.A., 2011. American society of clinical oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J. Clin. Oncol.. 29, 3328 – 3330.
dc.identifier.citedreferenceCarlson, R.W., Allred, D.C., Anderson, B.O., Burstein, H.J., Carter, W.B., Edge, S.B., Erban, J.K., Farrar, W.B., Forero, A., Giordano, S.H., Goldstein, L.J., Gradishar, W.J., Hayes, D.F., Hudis, C.A., Ljung, B.M., Mankoff, D.A., Marcom, P.K., Mayer, I.A., McCormick, B., Pierce, L.J., Reed, E.C., Sachdev, J., Smith, M.L., Somlo, G., Ward, J.H., Wolff, A.C., Zellars, R., 2011. Invasive breast cancer. J. Natl. Compr. Canc. Netw.. 9, 136 – 222.
dc.identifier.citedreferenceCristofanilli, M., Budd, G.T., Ellis, M.J., Stopeck, A., Matera, J., Miller, M.C., Reuben, J.M., Doyle, G.V., Allard, W.J., Terstappen, L.W., Hayes, D.F., 2004. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med.. 351, 781 – 791.
dc.identifier.citedreferenceDomchek, S.M., Friebel, T.M., Singer, C.F., Evans, D.G., Lynch, H.T., Isaacs, C., Garber, J.E., Neuhausen, S.L., Matloff, E., Eeles, R., Pichert, G., Van t’veer, L., Tung, N., Weitzel, J.N., Couch, F.J., Rubinstein, W.S., Ganz, P.A., Daly, M.B., Olopade, O.I., Tomlinson, G., Schildkraut, J., Blum, J.L., Rebbeck, T.R., 2010. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 304, 967 – 975.
dc.identifier.citedreferenceEarly Breast Cancer Trialists’ Collaborative Group (EBCTCG), 2011. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 378, 771 – 784.
dc.identifier.citedreferenceEaston, D.F., Ford, D., Bishop, D.T., 1995. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am. J. Hum. Genet.. 56, 265 – 271.
dc.identifier.citedreferenceFisher, B., Costantino, J.P., Wickerham, D.L., Redmond, C.K., Kavanah, M., Cronin, W.M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., Daly, M., Wieand, S., Tan-Chiu, E., Ford, L., Wolmark, N., 1998. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst.. 90, 1371 – 1388.
dc.identifier.citedreferenceFreidlin, B., McShane, L.M., Korn, E.L., 2010. Randomized clinical trials with biomarkers: design issues. J. Natl. Cancer Inst.. 102, 152 – 160.
dc.identifier.citedreferenceGilligan, T.D., Seidenfeld, J., Basch, E.M., Einhorn, L.H., Fancher, T., Smith, D.C., Stephenson, A.J., Vaughn, D.J., Cosby, R., Hayes, D.F., 2010. American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. J. Clin. Oncol.. 28, 3388 – 3404.
dc.identifier.citedreferenceHall, J.M., Lee, M.K., Newman, B., Morrow, J.E., Anderson, L.A., Huey, B., King, M.C., 1990. Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 250, 1684 – 1689.
dc.identifier.citedreferenceHammond, M.E., Hayes, D.F., Dowsett, M., Allred, D.C., Hagerty, K.L., Badve, S., 2010. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol..
dc.identifier.citedreferenceHarris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M.R., Hayes, D.F., Bast, R.C., 2007. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol.. 25, 5287 – 5312.
dc.identifier.citedreferenceHayes, D.F., Bast, R.C., Desch, C.E., Fritsche, H., Kemeny, N.E., Jessup, J.M., Locker, G.Y., Macdonald, J.S., Mennel, R.G., Norton, L., Ravdin, P., Taube, S., Winn, R.J., 1996. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J. Natl. Cancer Inst.. 88, 1456 – 1466.
dc.identifier.citedreferenceInnocenti, F., Ratain, M.J., 2006. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Pharmacogenomics. 7, 1211 – 1221.
dc.identifier.citedreferenceIoannidis, J.P., Panagiotou, O.A., 2011. Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. JAMA. 305, 2200 – 2210.
dc.identifier.citedreferenceKauff, N.D., Satagopan, J.M., Robson, M.E., Scheuer, L., Hensley, M., Hudis, C.A., Ellis, N.A., Boyd, J., Borgen, P.I., Barakat, R.R., Norton, L., Castiel, M., Nafa, K., Offit, K., 2002. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med.. 346, 1609 – 1615.
dc.identifier.citedreferenceKhatcheressian, J.L., Wolff, A.C., Smith, T.J., Grunfeld, E., Muss, H.B., Vogel, V.G., Halberg, F., Somerfield, M.R., Davidson, N.E., 2006. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J. Clin. Oncol.. 24, 5091 – 5097.
dc.identifier.citedreferenceLin, K., Lipsitz, R., Miller, T., Janakiraman, S., 2008. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann. Intern. Med.. 149, 192 – 199.
dc.identifier.citedreferenceLocker, G.Y., Hamilton, S., Harris, J., Jessup, J.M., Kemeny, N., Macdonald, J.S., Somerfield, M.R., Hayes, D.F., Bast, R.C., 2006. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J. Clin. Oncol.. 24, 5313 – 5327.
dc.identifier.citedreferenceMcShane, L.M., Altman, D.G., Sauerbrei, W., Taube, S.E., Gion, M., Clark, G.M., 2005. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br. J. Cancer. 93, 387 – 391.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
mol2201262140.pdf
Size:
212.3KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.